Pfizer v. Synthon: Palbociclib (IBRANCE®) Patent Dispute Dismissed After 1,030 Days
Pfizer and affiliated entities brought infringement claims against Synthon Pharmaceuticals over generic versions of IBRANCE® (palbociclib tablets) in the Middle District of North Carolina. The parties entered into a settlement and license agreement, leading to dismissal after nearly three years. The court retained jurisdiction to enforce the stipulated order.
Pfizer's IBRANCE® Patent Portfolio Tested Against Synthon's Generic Entry
On February 25, 2021, Pfizer Inc., Warner-Lambert Company LLC, PF PRISM C.V., Pfizer Manufacturing Holdings LLC, and PF PRISM IMB B.V. (collectively, the Pfizer entities) filed suit in the Middle District of North Carolina against Synthon Pharmaceuticals, Inc., Synthon B.V., and Synthon International Holding B.V. The complaint charged infringement of four U.S. patents — RE47,739, US7456168, US6936612, and US10723730 — in connection with Synthon's proposed generic palbociclib tablets at 75 mg, 100 mg, and 125 mg dosage strengths, the active ingredient in Pfizer's branded oncology product IBRANCE®.
The case closed on December 22, 2023 — 1,030 days after filing — when the parties filed a joint stipulation and order of dismissal, which the court entered. The recorded basis of termination is 'Case Dismissed.' The docket order states that all claims and counterclaims are dismissed without prejudice, that the parties have entered into a settlement and license agreement governing Synthon's conduct with respect to the accused product in the United States, and that the stipulation shall not act as an adjudication on the merits. Each party bears its own costs, attorneys' fees, and expenses. The court expressly retained jurisdiction to enforce the stipulation and to resolve the pending motion to seal filed November 27, 2023.
The 1,030-day duration is broadly consistent with contested ANDA patent litigation timelines in pharmaceutical cases, which frequently resolve through licensing before trial. The specific commercial terms of the settlement and license agreement — including any launch date provisions, royalty structure, or field restrictions — are not disclosed in the available public record. The pending motion to seal suggests that at least some materials filed in the case may remain confidential.
See Complete Case & Patent Analysis →Filing to Case Dismissed in 1030 days
1,030 days from filing to dismissal — a typical lifespan for complex ANDA/Hatch-Waxman pharmaceutical patent disputes
USRE047739, US7456168, US6936612 & US10723730 — Palbociclib CDK4/6 inhibitor patents
Any company developing, formulating, or seeking to commercialise a generic or biosimilar CDK4/6 inhibitor — particularly palbociclib — in the United States should treat Pfizer's four-patent cluster as a primary clearance target. The patents were not invalidated in this proceeding, and USRE047739E's reissue status makes it especially resilient to standard prior-art challenges. Generic manufacturers with pending or planned palbociclib ANDAs face direct infringement exposure across compound, formulation, and method claims.
Official order — verbatim text
The stipulated order records that all claims and counterclaims are dismissed without prejudice and expressly states that the order shall not act as an adjudication on the merits. The court retained jurisdiction to enforce the stipulation and resolve the pending motion to seal, indicating the settlement and license agreement is court-supervised. The underlying validity and infringement questions concerning the four asserted palbociclib patents were not resolved by the court.
Case dismissed: what the stipulated order means for both parties
Stipulated dismissal without prejudice — no merits adjudication
The parties filed a joint stipulation dismissing all claims and counterclaims without prejudice. The order expressly states it shall not act as an adjudication on the merits. The court retained jurisdiction to enforce the stipulation and to rule on the pending motion to seal. A without-prejudice dismissal means neither party obtained a court ruling on infringement or validity of the four asserted patents.
Without prejudice — no merits rulingPfizer secures control over Synthon's U.S. market conduct via licensing
The stipulation records that the parties entered into a settlement and license agreement governing Synthon's ability to make, use, offer for sale, or sell the accused palbociclib product in the United States. Pfizer's four asserted patents were not adjudicated, leaving their validity and enforceability intact. The specific commercial terms — including any authorised launch date or royalty — are not disclosed in the available public record.
Patents not invalidatedSynthon's U.S. commercial conduct governed by undisclosed licence terms
Synthon and its affiliates are bound by the settlement and license agreement with respect to the accused generic palbociclib tablets in the United States. The order confirms Synthon will not commercialise the accused product except as provided in that agreement. No finding of infringement was entered. The specific scope of the licence — including any authorised launch window — is not disclosed in the available public record.
Conduct limited by licencePalbociclib generic entry remains contingent on undisclosed licence terms
The resolution is consistent with the common Hatch-Waxman pattern in which branded pharmaceutical companies resolve ANDA litigation through licensing rather than trial, preserving patent rights while potentially allowing controlled generic entry. The IBRANCE® franchise patents remain valid and unadjudicated, maintaining Pfizer's litigation position against other prospective generic entrants. The terms that govern any Synthon commercial launch are not publicly available.
Generic entry terms undisclosedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | PF Prism C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Pfizer Manufacturing Holdings, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | PF Prism Ibm C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Warner Lambert Company, LLC | Company | Search in Eureka ↗ |
| Defendant | Synthon Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Synthon, BV | Individual | Search in Eureka ↗ |
| Co-Defendant | Synthon International Holding, BV | Company | Search in Eureka ↗ |
| Plaintiff counsel | ALLISON MULLINS | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Andrew L. Hoffman | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher J. Mandernach | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | David I. Berl | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kevin D. Hoagland-hanson | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Leslie Cooper Harrell | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Seth R. Bowers | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Xun Liu | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Mullins Duncan Harrell & Russell, PLLC | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Williams & Connolly, LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Brett A. Postal | Attorney | Counsel for Synthon Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Edward A. Figg | Attorney | Counsel for Synthon Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Jennifer P. Nock | Attorney | Counsel for Synthon Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Rachel M. Echols | Attorney | Counsel for Synthon Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert Joseph Morris | Attorney | Counsel for Synthon Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Rothwell, Figg, Ernst & Manbeck, PC | Law Firm | Representing Synthon Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Smith Anderson Blount Dorsett Mitchell & Jernigan | Law Firm | Representing Synthon Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | North Carolina Middle District CourtSearch in Eureka ↗ |
R&D signals in the CDK4/6 inhibitor and palbociclib patent space
Forward-looking patent intelligence on Pfizer's palbociclib portfolio, CDK4/6 inhibitor filing trends, Synthon's generic pharmaceutical IP posture, and adjacent oncology formulation opportunities.
Pfizer's CDK4/6 inhibitor portfolio extends well beyond the four asserted patents
Pfizer and Warner-Lambert hold a multi-layered patent estate around palbociclib spanning compound, formulation, method-of-treatment, and combination-therapy claims. Mapping this portfolio reveals the breadth of IP protection around IBRANCE® and identifies which claims are most likely to be asserted in future ANDA proceedings.
Pfizer palbociclib portfolioCDK4/6 inhibitor patent filings are expanding into combination and resistance-overcoming claims
Beyond first-generation CDK4/6 inhibitor compound patents, recent filings from multiple pharma innovators target combination regimens, biomarker-driven patient selection, and mechanisms to overcome acquired resistance. This filing trend signals where the next wave of patent litigation in this oncology class is likely to emerge.
CDK4/6 filing trendsSynthon's generic pharmaceutical patent activity in oncology solid dosage forms
Synthon's patent filings in generic pharmaceutical formulation — particularly solid oral dosage forms for oncology actives — indicate its R&D capabilities and potential ANDA pipeline. Analysing Synthon's own IP activity can signal which additional branded oncology products may face generic entry challenges from this organisation.
Synthon generic oncology IPPaediatric, novel salt, and amorphous form claims remain underexplored near palbociclib
Patent mapping around palbociclib suggests potential white space in paediatric formulation claims, alternative crystalline polymorphs, and co-crystal or amorphous solid dispersion approaches not covered by the four asserted patents. These areas may represent lower-litigation-risk formulation strategies for generic or 505(b)(2) applicants seeking market entry.
Formulation white spaceSimilar ANDA patent disputes: CDK4/6 inhibitors and branded oncology generics
Explore comparable Hatch-Waxman infringement actions involving CDK4/6 inhibitor patents and branded oncology products litigated in federal district courts.
What this case signals for the CDK4/6 inhibitor IP landscape
Pfizer's four-patent assertion strategy and licensing resolution carry clear signals for generic manufacturers and IP teams tracking the palbociclib space.
Four-patent assertion strategy raises the cost of generic entry for palbociclib
Pfizer asserted a layered portfolio — a reissue patent, two compound/formulation patents, and a later-filed patent — against Synthon's ANDA. This multi-patent approach is consistent with Hatch-Waxman practice designed to maximise the litigation burden on generic challengers and preserve multiple paths to injunctive relief.
Without-prejudice dismissal leaves Pfizer's patents fully available for future enforcement
Because the case ended without any adjudication on the merits, RE47,739, US7456168, US6936612, and US10723730 remain unchallenged by court ruling. Other ANDA filers targeting palbociclib will face the same patent landscape with no estoppel benefit from the Synthon proceedings.
Pfizer v Synthon — key questions answered
Pfizer and co-plaintiffs asserted four patents: USRE047739E, US7456168B2, US6936612B2, and US10723730B2, all relating to the palbociclib CDK4/6 inhibitor compound and formulations underlying IBRANCE®. The stipulated dismissal order specifically recites USRE047739 as the patent charged.
The case was dismissed by a joint stipulation and order entered December 22, 2023. The recorded basis of termination is 'Case Dismissed.' The docket order states all claims and counterclaims are dismissed without prejudice, that the parties entered a settlement and license agreement, and that the order is not an adjudication on the merits. The specific terms of the agreement are not publicly disclosed.
USRE047739E is a reissue of an earlier palbociclib patent, meaning its claims were corrected or broadened by the USPTO after original grant. Reissue patents carry an independent presumption of validity. For generic manufacturers, this means prior-art challenges to the original patent may not defeat the reissued claims, raising the cost and complexity of ANDA paragraph IV certification against this patent.
No. The stipulated dismissal order expressly states that it shall not act as an adjudication on the merits. All four asserted patents — USRE047739, US7456168, US6936612, and US10723730 — emerged from this litigation with no court ruling on their validity or infringement, leaving them fully enforceable against future generic entrants.
The court retained jurisdiction over the parties for two purposes: enforcing the stipulation and order of dismissal, and deciding the motion to seal filed November 27, 2023. Retained jurisdiction in settlement dismissals typically means either party can return to the same court to enforce the agreed terms without filing a new action, though the specific provisions it is empowered to enforce depend on the undisclosed settlement and license agreement.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.